Nutrients 2018, 10, 1243; doi:10.3390/nu10091243
www.mdpi.com/journal/nutrients

1. Introduction

Accumulating evidence from experimental [1–5] and observational epidemiological [6–10] studies indicates that vitamin D may play a role in Alzheimer’s disease (AD). Moreover, Mendelian randomization studies have shown a suggestive inverse association between genetically predicted serum 25-hydroxyvitamin D (S-25OH) concentrations, based on four single-nucleotide polymorphisms (SNPs), and AD [11,12]. Both vitamin D receptors and 1α-hydroxylase, the enzyme responsible for the formation of the biologically active form of vitamin D (1, 25-dihydroxyvitamin D), are present in the hippocampus [13]. The activity of 1α-hydroxylase is stimulated by parathyroid hormone (PTH), and receptors for this hormone are also found in the brain [14]. Elevated serum PTH (S-PTH) concentrations have been linked to poor cognition, vascular dementia, and all-cause dementia in some studies [15,16], but whether S-PTH concentrations affect the risk of AD specifically is unclear. S-PTH and S-25OH are inversely interrelated [17] and there is a need to further disentangle their effects on AD.

To provide insights into the role of PTH in AD, we performed a Mendelian randomization study to genetically predict the association of S-PTH concentrations with AD using data for five SNPs explaining 4.2% of the variance in S-PTH concentrations [18]. We also conducted an updated...
Mendelian randomization analysis of vitamin D and AD by using data for seven SNPs explaining about 7.5% of the variance in S-25OHD concentrations [19,20].

2. Methods

2.1. Study Design and Data Sources

We conducted a two-sample Mendelian randomization study using SNPs associated with S-PTH or S-25OHD as instrumental variables. We selected the SNPs associated with S-PTH or S-25OHD concentrations at genome-wide significance ($p < 5 \times 10^{-8}$) in previously published genome-wide association studies of respectively 29,155 [18] and 79,366 [19] individuals of European ancestry (Table 1). None of the SNPs within each trait were in linkage disequilibrium ($r^2 < 0.05$). In addition, for S-25OHD concentrations, we included the low-frequency SNP (rs10741657) of large effect on S-25OHD that was described in a genome-wide association study of 42,274 individuals of European ancestry [19].

This variant in CYP2R1 is not in linkage disequilibrium with the other common CYP2R1 variant ($r^2$ between the two SNPs = 0.03) (Table 1) [20].

Summary-level data ($\beta$-coefficients and standard errors) for the associations of the five S-PTH-associated SNPs and seven S-25OHD-associated SNPs with AD were available from the International Genomics of Alzheimer’s Project (IGAP), comprising 17,008 cases of AD and 37,154 controls of European ancestry [21]. All AD cases were confirmed by standardized diagnostic criteria (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA); Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)) [21].

This study is based on publicly available summarized (i.e., aggregated) data. Individual studies within each genome-wide association study received approval from a relevant Institutional Review Board, and informed consent was obtained from participants or from a caregiver, legal guardian, or other proxy.

Table 1. Characteristics of the single nucleotide polymorphisms associated with S-PTH and S-25OHD concentrations and their associations with AD.

| Exposure | SNP | Chr | Nearby Gene | EA * | EAF | Associations with Exposure | Associations with AD |
|----------|-----|-----|-------------|------|-----|----------------------------|----------------------|
| S-PTH    | rs6127099 | 20  | CYP24A1     | T    | 0.34 | 0.07, 0.003, 2.4 × 10^{-72} | 0.028, 0.019, 0.155  |
| S-PTH    | rs4074995 | 5   | RG3H4       | G    | 0.71 | 0.03, 0.003, 3.3 × 10^{-23} | 0.012, 0.018, 0.482  |
| S-PTH    | rs219779 | 21  | CLDN14      | G    | 0.75 | 0.04, 0.003, 8.9 × 10^{-22} | 0.023, 0.018, 0.202  |
| S-PTH    | rs4443100 | 22  | RTDR1       | G    | 0.32 | 0.02, 0.003, 4.1 × 10^{-11} | 0.005, 0.017, 0.773  |
| S-PTH    | rs73186030 | 3  | CASR        | T    | 0.14 | 0.03, 0.004, 1.2 × 10^{-9}  | -0.032, 0.022, 0.151 |
| S-25OHD  | rs3755967 | 4   | GC           | C    | 0.72 | 0.089, 0.002, 4.74 × 10^{-343} | -0.036, 0.017, 0.034 |
| S-25OHD  | rs117913124 | 11  | CYP2R1       | G    | 0.975 | 0.430, 0.020, 1.50 × 10^{-68} | -0.057, 0.065, 0.378 |
| S-25OHD  | rs12785878 | 11  | DHCR7       | T    | 0.75 | 0.036, 0.002, 3.80 × 10^{-43} | -0.022, 0.018, 0.208 |
| S-25OHD  | rs10741657 | 11  | CYP2R1      | A    | 0.40 | 0.031, 0.002, 2.05 × 10^{-46} | -0.011, 0.016, 0.492 |
| S-25OHD  | rs17216707 | 20  | CYP24A1     | T    | 0.79 | 0.026, 0.003, 8.14 × 10^{-23} | -0.045, 0.022, 0.038 |
| S-25OHD  | rs10745742 | 12  | AMDHD1      | T    | 0.40 | 0.017, 0.002, 1.88 × 10^{-14} | -0.006, 0.016, 0.691 |
| S-25OHD  | rs8018720 | 14  | SEC23A      | G    | 0.18 | 0.017, 0.003, 4.72 × 10^{-9}   | -0.012, 0.021, 0.584 |

Abbreviations: Chr, chromosome; EA, effect allele; EAF, effect allele frequency; SE, standard error. * Allele associated with higher concentrations of the exposure. † $\beta$-coefficients of the exposure-increasing allele on natural log-transformed concentrations of S-PTH (obtained from Robinson-Cohen et al. [18]) and S-25OHD (obtained from Jiang et al. [19]), if not otherwise indicated. ‡ $\beta$-coefficients of the exposure-increasing allele on log odds ratio of AD (obtained from Lambert et al. [21]). § SNPs rs10745742 was not available in the dataset for AD. Therefore, rs1968487 was used as proxy ($r^2$ between these two SNPs = 1.0). ‡ $\beta$-coefficient of the exposure-increasing allele on standard deviations of the standardized log-transformed S-25OHD concentrations (obtained from Manousaki et al. [20]).

2.2. Mendelian Randomization Analyses

The inverse-variance weighted method was used in the primary analysis [22]. In sensitivity analyses, the weighted median and MR-Egger methods were used to explore pleiotropy. The Mendelian randomization estimates were scaled per one standard deviation (SD) of ln-transformed S-PTH and
S-25OHD. Approximate SDs were derived from the population-based Swedish Mammography Cohort Clinical study [23] and was 0.33 ln-pg/mL for S-PTH and 0.33 ln-nmol/L for S-25OHD. Analyses were conducted using Stata (StataCorp, College Station, TX, USA).

3. Results

There was no significant association between genetically higher S-PTH concentrations and AD (odds ratio (OR) = 1.11; 95% confidence interval (CI), 0.97–1.26; p = 0.12) (Figure 1). The lack of association remained in a sensitivity analysis using the weighted median method (OR = 1.14; 95% CI, 0.97–1.34; p = 0.10). There was no evidence of pleiotropy in the MR-Egger analysis (intercept: −0.013 (95% CI −0.055 to 0.029), p = 0.55).

All seven S-25OHD-increasing alleles were inversely associated with AD and two of the associations were statistically significant (p < 0.05) (Table 1). In the Mendelian randomization analysis using information for all seven SNPs, the OR of AD per genetically-predicted one SD increase of serum S-25OHD concentration was 0.86 (95% CI 0.78–0.94; p = 0.002), without heterogeneity among individual SNPs (Figure 2). Results were robust in a sensitivity analysis using the weighted median method (OR = 0.87; 95% CI 0.78–0.98; p = 0.02). There was no evidence of pleiotropy in the MR-Egger analysis (intercept: −0.008 (95% CI −0.032 to 0.016), p = 0.51).

**Figure 1.** Association between a genetically-predicted one standard deviation increase of S-PTH concentration and AD.

**Figure 2.** Association between a genetically predicted one standard deviation increase of S-25OHD concentration and Alzheimer’s disease. rs1968487 was used as proxy SNP for rs10745742 (r² between these two SNPs = 1.0).
4. Discussion

This Mendelian randomization study provides strong evidence that higher S-25OHD concentrations are associated with a reduced risk of AD. Genetically higher S-PTH concentrations were not associated with AD, but we cannot rule out that a weak association may have been overlooked.

Previous Mendelian randomization analyses have demonstrated that four S-25OHD-associated SNPs in or near GC, DHCR7, CYP2R1, and CYP24A1 and a combined genetic risk score of those genetic variants are associated with AD \( (p = 0.01) \) [11,12]. The present analysis extends those results by showing that three additional S-25OHD-associated SNPs are associated with AD in the same direction and of the same magnitude, and a combined score of all seven SNPs shows that each SD increment of S-25OHD concentration (about 20–30 nmol/L or 8–12 ng/ml) is associated with a 14% reduced risk of AD \( (p = 0.002) \).

Our results are consistent with most [6–9] but not all [24,25] observational prospective studies, which have found that low pre-diagnostic S-25OHD concentrations are associated with an increased risk of AD. The reason for the inconsistent results among observational studies could be related to small sample sizes and, thus, low power in some of the studies, as well as differences in average S-25OHD concentrations among individuals in the reference group and the group defined as having low vitamin D status. Case-control and cross-sectional studies have shown a lower mean S-25OHD concentration in AD patients than in controls [10], but reverse causality is a potential concern in such studies since AD patients may have reduced their outdoor activities or changed their diet, potentially leading to decreased S-25OHD concentrations.

Studies on vitamin D and cognitive outcomes have generally shown no association. A Mendelian randomization study found no association between a genetic risk score of SNPs in the DHCR7 and CYP2R1 gene regions and cognitive performance [26]. Randomized controlled trials of vitamin D supplementation on cognitive outcomes in patients suffering from AD are limited. One trial showed that treatment with vitamin D plus memantine was associated with improvement in cognition compared with vitamin D or memantine alone [27]. Two other trials failed to find an impact on vitamin D supplementation on cognitive performance in nursing home residents and individuals with mild-moderate severe AD [28,29]. A post hoc analysis of the Women’s Health Initiative, including 4143 women aged 65 years and older without probable dementia, showed no difference in incident dementia or cognitive function between women who received 400 IU of vitamin D3 combined with 1000 mg of calcium and women who received placebo [30]. Whether long-term vitamin D supplementation prevents the onset or progression of AD is unknown and merits evaluation in a randomized controlled trial. Such a trial may, however, not be feasible to conduct due to the large sample size and long follow-up required to detect an association.

Vitamin D affects several mechanisms of AD pathogenesis, including the production, aggregation, clearance, and degradation of amyloid β peptides, as well as neurogenesis and Tau phosphorylation [1–5]. For instance, experimental studies in mouse models of AD have shown that vitamin D treatment improves neurogenesis [3] and reduces amyloid β deposition, particularly in the hippocampus where the vitamin D receptor is abundant [4]. Vitamin D is also involved in the transcriptional activation of the tryptophan hydroxylase 2 gene, which encodes the rate-limiting enzyme in serotonin synthesis [31]. Serotonin may play a role in AD by influencing neurogenesis and amyloid plaque load [32].

The association between S-PTH and dementia has been examined in a few prospective and case-control studies [15,16]. In a prospective cohort of 988 Swedish men, high S-PTH concentrations were significantly positively associated with risk of vascular dementia (41% increase in risk per 1 SD increase in S-PTH) but were not associated with risk of AD or other dementias [16]. Another prospective study found that elevated S-PTH concentrations were associated with a significant increased risk of all-cause dementia during the one- and five-year follow-up, but not at the ten-year follow-up [33]. Reverse causality may explain the observed association in that study since a large proportion of participants had cognitive impairment at baseline and the association was not consistent at the ten-year
follow-up. Two small case-control studies reported significantly higher S-PTH concentrations among patients with dementia [34] or AD specifically [35] compared with controls. However, case-control studies are susceptible to reverse causation bias.

A major strength of the Mendelian randomization approach is that reverse causation bias is avoided because genetic variants are fixed at conception. Another strength is that confounding is reduced by the use of genetic variants as proxies for the exposure and that long-term exposure is investigated. In addition, since there is an inverse physiological correlation between S-PTH and S-25OHD [17] their independent effects cannot easily be evaluated by a non-instrumental study design.

A limitation is potential bias due to pleiotropy, which occurs when one gene influences multiple traits. We cannot entirely exclude that the SNPs used as instruments in the present study may affect the risk of AD through mechanisms other than their effects on S-25OHD. However, findings were similar in a complementary analysis using the weighted median method, which provide robust estimates when at least 50% of the weight in the analysis derives from valid instruments. We found no evidence of directional pleiotropy in the MR-Egger analysis but this method has low power when the number of SNPs is few. Other modifiable exposures, such as cardiometabolic risk factors (e.g., body mass index, waist-to-hip ratio, blood pressure, fasting insulin, fasting glucose, and cholesterol levels), were not associated with AD in a recent Mendelian randomization study based on the IGAP dataset [12] and, therefore, are unlikely confounders of the association of S-25OH with AD. Another possible concern in Mendelian randomization studies is population stratification. Nonetheless, this potential source of bias was reduced since the genome-wide association studies on S-25OH and AD only included European-descent individuals.

5. Conclusions

This study indicates that genetically higher concentrations of S-25OHD, but not S-PTH, are associated with AD. This suggests that maintenance of an adequate vitamin D status throughout life may reduce the risk of AD.

Author Contributions: S.C.L. designed the research, handled funding, performed the statistical analysis, interpreted the data, and drafted the manuscript. M.T., H.S.M., and K.M. interpreted the data and made critical revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgments: This study was supported by a research grant from the Swedish Brain Foundation. Hugh Markus is supported by an NIHR Senior Investigator award. His and Matthew Traylor work is supported by infrastructural support from the Cambridge University Hospitals Trust NIHR Biomedical Research Centre. The authors thank the International Genomics of Alzheimer’s Project (IGAP) for providing summary results data for these analyses.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Holick, M.F. Vitamin D and brain health: The need for vitamin D supplementation and sensible sun exposure. *J. Intern. Med.* 2015, 277, 90–93. [CrossRef] [PubMed]
2. Annweiler, C.; Dursun, E.; Feron, F.; Gezen-Ak, D.; Kalueff, A.V.; Littlejohns, T.; Llewellyn, D.J.; Millet, P.; Scott, T.; Tucker, K.L.; et al. ‘Vitamin D and cognition in older adults’: Updated international recommendations. *J. Intern. Med.* 2015, 277, 45–57. [CrossRef] [PubMed]
3. Morello, M.; Landel, V.; Lacassagne, E.; Baranger, K.; Annweiler, C.; Feron, F.; Millet, P. Vitamin D improves neurogenesis and cognition in a mouse model of Alzheimer’s Disease. *Mol. Neurobiol.* 2018, 55, 3463–6479. [CrossRef] [PubMed]
4. Durk, M.R.; Han, K.; Chow, E.C.; Ahrens, R.; Henderson, J.T.; Fraser, P.E.; Pang, K.S. 1alpha, 25-Dihydroxyvitamin D3 reduces cerebral amyloid-beta accumulation and improves cognition in mouse models of Alzheimer’s disease. *J. Neurosci.* 2014, 34, 7091–7101. [CrossRef] [PubMed]
5. Keeney, J.T.; Butterfield, D.A. Vitamin D deficiency and Alzheimer disease: Common links. *Neurobiol. Dis.* 2015, 84, 84–98. [CrossRef] [PubMed]
6. Afzal, S.; Bojesen, S.E.; Nordestgaard, B.G. Reduced 25-hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. *Alzheimers Dement.* 2014, 10, 296–302. [CrossRef] [PubMed]

7. Littlejohns, T.J.; Henley, W.E.; Lang, I.A.; Annweiler, C.; Beaucet, O.; Chaves, P.H.; Fried, L.; Kestenbaum, B.R.; Kuller, L.H.; Langa, K.M.; et al. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology* 2014, 83, 920–928. [CrossRef] [PubMed]

8. Feart, C.; Helmer, C.; Merle, B.; Herrmann, F.R.; Annweiler, C.; Dartigues, J.F.; Delcourt, C.; Samieri, C. Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer disease in older adults. *Alzheimers Dement.* 2017, 13, 1207–1216. [CrossRef] [PubMed]

9. Licher, S.; de Bruijn, R.; Wolters, F.J.; Zillikens, M.C.; Ikram, M.A.; Ikram, M.K. Vitamin D and the risk of dementia: The rotterdam study. *J. Alzheimers Dis.* 2017, 60, 989–997. [CrossRef] [PubMed]

10. Balion, C.; Griffith, L.E.; Strifler, L.; Henderson, M.; Patterson, C.; Heckman, G.; Llewellyn, D.J.; Raina, P. Vitamin D, cognition, and dementia: A systematic review and meta-analysis. *Neurology* 2012, 79, 1397–1405. [CrossRef] [PubMed]

11. Robinson-Cohen, C.; Lutsey, P.L.; Fried, L.; Kestenbaum, B.R.; Kuller, L.H.; Langa, K.M.; et al. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology* 2016, 87, 2567–2574. [CrossRef] [PubMed]

12. Larsson, S.C.; Traylor, M.; Malik, R.; Dichgans, M.; Burgess, S.; Markus, H.S. Modifiable pathways in Alzheimer’s disease: Mendelian randomization analysis. *BMJ* 2017, 359, j3375. [CrossRef] [PubMed]

13. Eyles, D.W.; Smith, S.; Kinobe, R.; Hewison, M.; McGrath, J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J. Chem. Neuroanat.* 2005, 29, 21–30. [CrossRef] [PubMed]

14. Usdin, T.B.; Gruber, C.; Bonner, T.I. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. *J. Biol. Chem.* 1995, 270, 15455–15458. [CrossRef] [PubMed]

15. Lourida, I.; Thompson-Coon, J.; Dickens, C.M.; Soni, M.; Kuzma, E.; Kos, K.; Llewellyn, D.J. Parathyroid hormone, cognitive function and dementia: A systematic review. *PLoS ONE* 2015, 10, e0127574. [CrossRef] [PubMed]

16. Hagstrom, E.; Kilander, L.; Nylander, R.; Larsson, S.C.; Traylor, M.; Malik, R.; Dichgans, M.; Burgess, S.; Markus, H.S. Modifiable pathways in Alzheimer’s disease: Mendelian randomization analysis. *BMJ* 2017, 359, j3375. [CrossRef] [PubMed]

17. Holick, M.F. Vitamin D deficiency. *N. Engl. J. Med.* 2007, 357, 266–281. [CrossRef] [PubMed]

18. Robinson-Cohen, C.; Luts, P.L.; Kleber, M.E.; Nielson, C.M.; Mitchell, B.D.; Bis, J.C.; Eny, K.M.; Portas, L.; Eriksson, J.; Lorentzon, M.; et al. Genetic variants associated with circulating parathyroid hormone. *J. Am. Soc. Nephrol.* 2017, 28, 1553–1565. [CrossRef] [PubMed]

19. Jiang, X.; O’Reilly, P.F.; Aschard, H.; Hsu, Y.H.; Richards, J.B.; Dupuis, J.; Ingelsson, E.; Karasik, D.; Pizl, S.; Berry, D.; et al. Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. *Nat. Commun.* 2018, 9, 260. [CrossRef] [PubMed]

20. Manousaki, D.; Duddling, T.; Haworth, S.; Hsu, Y.H.; Liu, C.T.; Medina-Gomez, C.; Voortman, T.; van der Velde, N.; Melhus, H.; Robinson-Cohen, C.; et al. Low-Frequency synonymous coding variation in CYP2R1 has large effects on vitamin D levels and risk of multiple sclerosis. *Am. J. Hum. Genet.* 2017, 101, 227–238. [CrossRef] [PubMed]

21. Lambert, J.C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellengue, D.; DeStafano, A.L.; Bis, J.C.; Beecham, G.W.; Grenier-Boley, B.; et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat. Genet.* 2013, 45, 1452–1458. [CrossRef] [PubMed]

22. Burgess, S.; Bowden, J.; Fall, T.; Ingelsson, E.; Thompson, S.G. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. *Epidemiology* 2018, 29, 30–42. [CrossRef] [PubMed]

23. Michielsson, K.; Wolk, A.; Byberg, L.; Mitchell, A.; Mallmin, H.; Melhus, H. The seasonal importance of serum 25-hydroxyvitamin D for bone mineral density in older women. *J. Intern. Med.* 2017, 281, 167–178. [CrossRef] [PubMed]

24. Olsson, E.; Byberg, L.; Karlstrom, B.; Cederholm, T.; Melhus, H.; Sjogren, P.; Kilander, L. Vitamin D is not associated with incident dementia or cognitive impairment: An 18-y follow-up study in community-living old men. *Am. J. Clin. Nutr.* 2017, 105, 936–953. [CrossRef] [PubMed]
25. Karakis, I.; Pase, M.P.; Beiser, A.; Booth, S.L.; Jacques, P.F.; Rogers, G.; DeCarli, C.; Vasan, R.S.; Wang, T.J.; Himali, J.J.; et al. Association of serum vitamin D with the risk of incident dementia and subclinical indices of brain aging: The framingham heart study. *J. Alzheimers Dis.* 2016, 51, 451–461. [CrossRef] [PubMed]

26. Maddock, J.; Zhou, A.; Cavadino, A.; Kuzma, E.; Bao, Y.; Smart, M.C.; Saum, K.U.; Schottker, B.; Engmann, J.; Kjaergaard, M.; et al. Vitamin D and cognitive function: A Mendelian randomization study. *Sci. Rep.* 2017, 7, 13230. [CrossRef] [PubMed]

27. Annweiler, C.; Herrmann, F.R.; Fantino, B.; Brugg, B.; Beuchet, O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: A pre-post pilot study. *Cogn. Behav. Neurol.* 2012, 25, 121–127. [CrossRef] [PubMed]

28. Stein, M.S.; Scherer, S.C.; Ladd, K.S.; Harrison, L.C. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer’s disease. *J. Alzheimers Dis.* 2011, 26, 477–484. [CrossRef] [PubMed]

29. Przybelski, R.; Agrawal, S.; Krueger, D.; Engelke, J.A.; Walbrun, F.; Binkley, N. Rapid correction of low vitamin D status in nursing home residents. *Osteoporos. Int.* 2008, 19, 1621–1628. [CrossRef] [PubMed]

30. Rossom, R.C.; Espeland, M.A.; Manson, J.E.; Dysken, M.W.; Johnson, K.C.; Lane, D.S.; LeBlanc, E.S.; Lederle, F.A.; Masaki, K.H.; Margolis, K.L. Calcium and vitamin D supplementation and cognitive impairment in the women’s health initiative. *J. Am. Geriatr. Soc.* 2012, 60, 2197–2205. [CrossRef] [PubMed]

31. Kaneko, I.; Sabir, M.S.; Dussik, C.M.; Whitfield, G.K.; Karrys, A.; Hsieh, J.C.; Haussler, M.R.; Meyer, M.B.; Pike, J.W.; Jurutka, P.W. 1,25-Dihydroxyvitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: Implication for behavioral influences of vitamin D. *FASEB J.* 2015, 29, 4023–4035. [CrossRef] [PubMed]

32. Larsson, S.C.; Markus, H.S. Branched-chain amino acids and Alzheimer’s disease: A Mendelian randomization analysis. *Sci. Rep.* 2017, 7, 13604. [CrossRef] [PubMed]

33. Bjorkman, M.P.; Sorva, A.J.; Tilvis, R.S. Does elevated parathyroid hormone concentration predict cognitive decline in older people? *Aging Clin. Exp. Res.* 2010, 22, 164–169. [CrossRef] [PubMed]

34. Kipen, E.; Helme, R.D.; Wark, J.D.; Flicker, L. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. *J. Am. Geriatr. Soc.* 1995, 43, 1088–1091. [CrossRef] [PubMed]

35. Ogihara, T.; Miya, K.; Morimoto, S. Possible participation of calcium-regulating factors in senile dementia in elderly female subjects. *Gerontology* 1990, 36, 25–30. [CrossRef] [PubMed]